Evidence map›Paper›PMID 40725043›Full record

ArticleInternational journal of molecular sciences2025

siRNA Features-Automated Machine Learning of 3D Molecular Fingerprints and Structures for Therapeutic Off-Target Data.

Michael Richter, Alem Admasu

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael RichterDepartment of Chemistry, Binghamton University, Binghamton, NY 13902, USA.ORCID 0009-0000-4538-9767
Alem AdmasuDepartment of Physics and Astronomy, Rutgers University, Piscataway, NJ 08854, USA.ORCID 0000-0003-2050-9448

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemical modifications are the standard for small interfering RNAs (siRNAs) in therapeutic applications, but predicting their off-target effects remains a significant challenge. Current approaches often rely on sequence-based encodings, which fail to fully capture the structural and protein-RNA interaction details critical for off-target prediction. In this study, we developed a framework to generate reproducible structure-based chemical features, incorporating both molecular fingerprints and computationally derived siRNA-hAgo2 complex structures. Using an RNA-Seq off-target study, we generated over 30,000 siRNA-gene data points and systematically compared nine distinct types of feature representation strategies. Among the datasets, the highest predictive performance was achieved by Dataset 3, which used extended connectivity fingerprints (ECFPs) to encode siRNA and mRNA features. An energy-minimized dataset (7R), representing siRNA-hAgo2 structural alignments, was the second-best performer, underscoring the value of incorporating reproducible structural information into feature engineering. Our findings demonstrate that combining detailed structural representations with sequence-based features enables the generation of robust, reproducible chemical features for machine learning models, offering a promising path forward for off-target prediction and siRNA therapeutic design that can be seamlessly extended to include any modification, such as clinically relevant 2'-F or 2'-OMe.

Indexed as

Machine LearningRNA, Small InterferingHumansRNA, Small Interferingargonautechemical modificationextended connectivity fingerprints (ECFPs)feature engineeringhAgo2machine learningmolecular dynamicsoff-target predictionsiRNAstructural modelingstructure-based modeling

Identifiers

PMID40725043
PMCPMC12296190

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.